{
}
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS following a recent management call.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investors are reminded of the risks involved, including the potential total loss of capital.
UBS has reaffirmed its "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS, following a recent management call. As of February 3, 2025, Sanofi's stock was trading at 104.38 euros, reflecting a slight increase of 0.19%.
Deutsche Bank analyst Emmanuel Papadakis upgraded Sanofi's stock from Sell to Hold, raising the price target to €100.00 from €85.00, following strong fourth-quarter results that indicated solid growth and reduced risks. The upgrade reflects improved sentiment towards Sanofi's strategy, particularly with the positive performance of Dupixent in the COPD market, and a clarified buyback program that alleviated merger concerns. Investors may interpret this as a sign of Sanofi's stability and potential for sustained growth.
UBS has increased its target price for Sanofi from 115 to 120 euros while maintaining a "Buy" rating, citing a strong fourth quarter and an impressive share buyback program. Analyst Jo Walton noted high single-digit growth for Dupixent and expressed confidence in the respiratory drug Beyfortus despite competition.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicines accounting for 59.3%. The company also focuses on human vaccines (17.4%) and consumer healthcare products (12%). By the end of 2023, Sanofi will operate 54 production sites globally, with significant sales in the United States (43%) and Europe (18.6%).
UBS has raised its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, with Dupixent continuing to show high single-digit growth. The company remains optimistic about its respiratory drug Beyfortus despite competition.
UBS has increased its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, while highlighting the continued growth of the drug Dupixent and confidence in the respiratory drug Beyfortus despite competition.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investors are reminded of the risks involved, including the potential total loss of capital.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for sanofi with target price of 120 euros
09:46 13.02.2025
UBS maintains buy rating for Sanofi with target price of 120 euros
12:48 03.02.2025
ubs upgrades sanofi to buy amid investment considerations and risks
12:48 03.02.2025
ubs maintains buy rating on sanofi with target price of 120 euros
11:48 03.02.2025
Deutsche Bank upgrades Sanofi stock to hold with increased price target
13:24 31.01.2025
ubs raises sanofi target price to 120 euros maintains buy rating
11:20 31.01.2025
sanofi's diverse portfolio drives strong sales across global markets
11:07 31.01.2025
ubs raises sanofi target price to 120 euros maintaining buy rating
11:07 31.01.2025
ubs raises sanofi target price to 120 euros maintaining buy rating
10:20 31.01.2025
ubs upgrades sanofi to buy amid investment considerations and risks
12:43 30.01.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
Market Analysis and Predictions
Banking Regulations
Industry Mergers & Acquisitions
CEO Changes
Global Trade Developments
Supply Chain Management
Workplace Trends
Hedge Funds & Private Equity
Startups & Entrepreneurship
Government Economic Policies
Central Bank Actions
Financial Scams and Security
Banking & Investment Regulations
Government Policies
Countries:
Companies:
BNP Paribas SA
Barclays PLC
Deutsche Bank RV Global PP
Tesla, Inc.
Raiffeisen Bank International AG
Apple Inc.
UniCredit S.p.A.
JPMorgan Chase & Co.
Strabag SE
Citigroup Inc.
The Goldman Sachs Group, Inc.
Kering S.A. (ADRs)
UBS Group AG
Bank of America Corporation
Morgan Stanley
Banco BPM S.p.A.
Berner Kantonalbank AG
Berkshire Hathaway Inc.
Standard Chartered PLC
Lam Research Corporation
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
Indian Rupee
British Pound Sterling
Japanese Yen
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
Russian Ruble
Brazilian Real
Filipino Peso
Malaysian Ringgit
United Arab Emirates Dirham
South African Rand
Indonesian Rupiah
South Korean Won
People: